Catheter Precision (VTAK) AI Stock Analysis

• Market Cap: $3.85M
• Dividend Yield: N/A
• Average Volume (3M): 309.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 37.61%
• EPS Growth: 68.37%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -12.53
• Shares Outstanding: 1,487,266
• 10 Day Avg. Volume: 759,143
• 30 Day Avg. Volume: 309,336
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 4.03
• Enterprise Value/Revenue: 25.86
• Enterprise Value/Gross Profit: 28.01
• Enterprise Value/Ebitda: -1.04
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: $2.50 ▼(-1.96% Downside)

VTAK's overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. The technical analysis indicates a bearish trend, further weighing down the score. The lack of earnings call data and corporate events means these factors do not influence the score.

Catheter Precision Business Overview & Revenue Model

Company Description

Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.

How the Company Makes Money

Catheter Precision generates revenue primarily through the sale of its electrophysiology systems and related consumables. The company’s revenue model is based on a combination of direct sales to hospitals and healthcare providers, along with recurring revenue from the sale of disposable catheters and accessories used in procedures. Additionally, Catheter Precision may engage in strategic partnerships with medical institutions and technology firms to enhance its product offerings and expand its market reach, contributing to its overall earnings.

Catheter Precision Financial Statement Overview

Summary

The financial performance of Catheter Precision is weak, with declining revenues, negative EBIT and net income margins, and ongoing negative free cash flow. Despite a manageable debt-to-equity ratio, the negative return on equity and cash flow challenges indicate significant financial difficulties.

Income Statement

The income statement reveals a significant decline in revenue from 2019 to 2024, with a negative revenue growth rate. Gross profit margin is positive, but both EBIT and net income margins are negative, indicating persistent operational losses. This suggests challenges in achieving profitability despite efforts to control costs.

Balance Sheet

The balance sheet highlights a moderately leveraged position with a debt-to-equity ratio that is manageable. However, the return on equity is negative due to continuing net losses, which is a concern for investor returns. The equity ratio shows a reasonable proportion of equity financing, suggesting some financial stability.

Cash Flow

Cash flow analysis shows ongoing negative free cash flow, indicating cash outflows that exceed inflows from operations. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. The company needs to improve operational efficiency to enhance cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	600.00K	420.00K	442.00K	14.00K	22.00K	4.41M
Gross Profit	554.00K	378.00K	412.00K	-147.00K	-1.54M	-1.08M
EBITDA	-14.85M	-11.30M	-15.11M	-22.37M	-25.85M	-33.30M
Net Income	-19.25M	-16.64M	-70.57M	-26.86M	-25.07M	-36.05M
Balance Sheet
Total Assets	25.56M	27.77M	30.74M	16.84M	21.04M	33.44M
Cash, Cash Equivalents and Short-Term Investments	1.71M	2.87M	3.56M	15.86M	15.04M	23.91M
Total Debt	15.06M	1.79M	372.00K	124.17K	2.26M	4.88M
Total Liabilities	19.01M	16.01M	9.54M	7.58M	7.37M	12.29M
Stockholders Equity	6.79M	11.76M	21.19M	9.26M	13.67M	21.15M
Cash Flow
Free Cash Flow	-7.66M	-9.34M	-20.70M	-22.59M	-27.89M	-28.37M
Operating Cash Flow	-7.65M	-9.27M	-20.62M	-22.57M	-27.63M	-28.30M
Investing Cash Flow	-10.00K	-67.00K	-61.00K	21.00K	3.80M	15.93M
Financing Cash Flow	8.12M	8.65M	8.39M	23.36M	14.96M	21.69M

Catheter Precision Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Negative. The current price of 2.55 is below the 20-day moving average (MA) of 2.60, below the 50-day MA of 2.66, and below the 200-day MA of 5.12, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.22 is Neutral, neither overbought nor oversold. The STOCH value of 16.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTAK.

Catheter Precision Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HSCS	45 Neutral	$9.11M	―	-193.24%	―	-66.40%	65.99%
VVOS	44 Neutral	$21.76M	―	-262.03%	―	2.65%	70.21%
NUWE	43 Neutral	$3.11M	―	―	―	-7.72%	99.54%
SINT	42 Neutral	$14.20M	―	-195.48%	―	-40.47%	96.14%
VTAK	41 Neutral	$3.85M	―	-179.11%	―	37.61%	68.37%
HIND	37 Underperform	$29.89M	―	-101.49%	―	-19.81%	93.32%

Catheter Precision Corporate Events

Catheter Precision Increases Authorized Shares to 500 Million

On October 10, 2025, Catheter Precision held a Special Meeting of stockholders where approximately 43.1% of the outstanding shares of common stock were represented. During the meeting, stockholders approved three proposals: an increase in authorized shares from 60 million to 500 million, the ratification of WithumSmith+Brown, PC as the independent accounting firm for 2026, and the potential adjournment or postponement of the meeting to solicit more votes if necessary.

The most recent analyst rating on (VTAK) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Catheter Precision stock, see the VTAK Stock Forecast page.

Catheter Precision’s LockeT Approved for UK Market

On August 18, 2025, Catheter Precision announced the approval of its suture retention device, LockeT, for commercialization in the United Kingdom. This approval marks a significant milestone for the company, enhancing its market presence in Europe following the CE Mark approval in May 2025. LockeT is designed to improve patient comfort and recovery, enabling earlier discharge after cardiac procedures, which aligns with the NHS’s efforts to reduce waiting lists. The partnership with distributor HC21 is expected to facilitate LockeT’s market entry and support healthcare systems in the UK.

Catheter Precision Implements 1-for-19 Reverse Stock Split

Catheter Precision, Inc. held its 2025 annual meeting of stockholders on July 25, 2025, where the proposal for a reverse stock split was approved. The company’s board of directors decided on a 1-for-19 reverse stock split, which became effective on August 15, 2025. This move reduced the number of issued and outstanding shares significantly but did not alter the total authorized capital stock. The reverse split aimed to consolidate shares while maintaining stockholder equity and voting power, with adjustments made to stock options and warrants accordingly.

Catheter Precision Approves Reverse Stock Split Plan

On July 25, 2025, Catheter Precision held its Annual Meeting of Stockholders, where six proposals were considered and approved, including the election of a director and several stock issuance proposals. A significant decision was the approval of a reverse stock split at a ratio of 1-for-19, effective August 15, 2025, aimed at maintaining the company’s compliance with NYSE American’s listing requirements. This reverse stock split will reduce the number of outstanding shares from approximately 23.3 million to 1.2 million, ensuring the company’s continued listing on its current exchange without altering stockholders’ equity percentage.